ProMIS Neurosciences Replaces CEO, Gail Farfel
Biotechnology company, ProMIS Neurosciences Inc. (Nasdaq: PMN), has announced it will replace its current Chief Executive Officer, Gail Farfel with Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, who will act as interim CEO. Dr. Farfel spent a little over 12 months in the role before stepping down to ‘pursue other opportunities’.
Commenting on the announcement, Gene Williams, Chairman of the Board of ProMIS, said that Mr. Warma’s appointment would provide a seamless transition as the Company remains focused on advancing its ongoing clinical program for PMN310 in Alzheimer’s disease.
“On behalf of the Board, I am thrilled to welcome Neil as our interim CEO. His leadership and his neuroscience background, combined with a profound understanding of our mission in novel drug development, positions the Company well for growth during this transition period. Under Neil’s guidance, we are confident in our ability to advance our ongoing clinical program and foster partnerships that will drive innovation in dementias and other neurodegenerative disease treatments. He has a strong business development background having negotiated several deals with large pharmaceutical companies, which will also be a focus of the Company going forward.”
Mr. Warma brings a wealth of industry knowledge and a passion for innovation, having served as an independent Director on the ProMIS Board since 2022. He has a proven track record of successfully leading and building biotech companies as a founder and executive leader, and strong experience advancing products from preclinical to commercialization. Mr. Warma has held senior leadership positions at Novartis, Opexa Therapeutics and I-Mab BioPharma, Inc. Most recently, he served as the CEO of Genexine, Inc. a South Korean-based biotech company, where he led the successful approval of the Company’s first commercial product.
ProMIS is focused on the development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA.
